Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MyStart Health vs Wisp

MyStart Health
Graded #168

Higher grade

vs+2.6999999999999886
Wisp
Graded #243

Lower grade

The verdict

MyStart Health takes it — 67.1/100 to 64.4/100.

MyStart Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyStart Health offers all-inclusive compounded semaglutide and tirzepatide at $299/month with a price-lock guarantee, same-day physician consultations, and 24/7 care team access.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWisp +2
48
50
Dose & formulationMyStart Health +7
83
76
Clinical oversightMyStart Health +2
84
82
Labs & monitoringMyStart Health +13
66
53
FulfillmentMyStart Health +12
78
66
Contract termsWisp +24
31
55
MyStart Health · left barWisp · right bar

The numbers

MetricMyStart HealthWisp
WeighScore67.1/10064.4/100
GradeCC
Scorecard rank#168#243
Semaglutide$299/mo (all doses, compounded)$225/mo (compounded oral)
Tirzepatide$299/mo (all doses, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
MyStart Health

Graded #168 · C

Strengths

  • Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
  • Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
  • 24/7 care team access with unlimited clinician messaging included
  • LegitScript certified
  • Clear Section 503A compounding disclosure on every landing page

Where it loses points

  • Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
  • Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
  • Very new company (incorporated May 2024) with a limited track record
  • Pharmacy partners not named, so 503A compliance can't be independently verified
Wisp

Graded #243 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • The $99/mo tirzepatide figure is a consultation-and-care subscription, not the medication: Zepbound is filled at a pharmacy of your choice at its own cost, which Wisp does not publish
  • The compounded semaglutide option is sublingual drops, which Wisp itself describes as less effective than injection
  • Brand-name access is a prescription, not a dispensed product, so the drug cost is outside anything quoted here

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard